1. Home
  2. NTLA vs SSII Comparison

NTLA vs SSII Comparison

Compare NTLA & SSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • SSII
  • Stock Information
  • Founded
  • NTLA 2014
  • SSII N/A
  • Country
  • NTLA United States
  • SSII India
  • Employees
  • NTLA N/A
  • SSII N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • SSII
  • Sector
  • NTLA Health Care
  • SSII
  • Exchange
  • NTLA Nasdaq
  • SSII Nasdaq
  • Market Cap
  • NTLA 1.2B
  • SSII 1.3B
  • IPO Year
  • NTLA 2016
  • SSII N/A
  • Fundamental
  • Price
  • NTLA $16.11
  • SSII $5.44
  • Analyst Decision
  • NTLA Buy
  • SSII
  • Analyst Count
  • NTLA 20
  • SSII 0
  • Target Price
  • NTLA $32.30
  • SSII N/A
  • AVG Volume (30 Days)
  • NTLA 4.8M
  • SSII 47.6K
  • Earning Date
  • NTLA 11-06-2025
  • SSII 11-14-2025
  • Dividend Yield
  • NTLA N/A
  • SSII N/A
  • EPS Growth
  • NTLA N/A
  • SSII N/A
  • EPS
  • NTLA N/A
  • SSII N/A
  • Revenue
  • NTLA $52,857,000.00
  • SSII $27,623,624.00
  • Revenue This Year
  • NTLA $8.90
  • SSII N/A
  • Revenue Next Year
  • NTLA N/A
  • SSII N/A
  • P/E Ratio
  • NTLA N/A
  • SSII N/A
  • Revenue Growth
  • NTLA 14.99
  • SSII 134.89
  • 52 Week Low
  • NTLA $5.90
  • SSII $2.48
  • 52 Week High
  • NTLA $23.76
  • SSII $22.42
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 81.73
  • SSII 37.95
  • Support Level
  • NTLA $10.89
  • SSII $5.35
  • Resistance Level
  • NTLA $12.03
  • SSII $7.00
  • Average True Range (ATR)
  • NTLA 0.93
  • SSII 0.56
  • MACD
  • NTLA 0.34
  • SSII -0.17
  • Stochastic Oscillator
  • NTLA 95.09
  • SSII 10.43

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About SSII SS Innovations International Inc.

SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.

Share on Social Networks: